Left Ventricular Dysfunction in Arrhythmogenic Cardiomyopathy: Association With Exercise Exposure, Genetic Basis, and Prognosis

Øyvind H. Lie, MD, PhD; Monica Chivulescu, MD; Christine Rootwell-Norberg, MD; Margareth Ribe, RN; Martin Proven Bogsrud, MD, PhD; Erik Lyseggen, MD, PhD; Jan Otto Beitnes, MD, PhD; Vibeke Almaas, MD, PhD; Kristina H. Haugaa, MD, PhD

BACKGROUND: Arrhythmogenic cardiomyopathy (AC) is characterized by biventricular dysfunction, exercise intolerance, and high risk of ventricular tachyarrhythmias and sudden death. Predisposing factors for left ventricular (LV) disease manifestation and its prognostic implication in AC are poorly described. We aimed to assess the associations of exercise exposure and genotype with LV dysfunction in AC, and to explore the impact of LV disease progression on adverse arrhythmic outcome.

METHODS AND RESULTS: We included 168 patients with AC (50% probands, 45% women, 40±16 years old) with 715 echocardiographic exams (4.1±1.7 exams/patient, follow-up 7.6 [interquartile range (IQR), 5.4–10.9] years) and complete exercise and genetic data in a longitudinal study. LV function by global longitudinal strain was −18.8% [IQR, −19.2% to −18.3%] at presentation and was worse in patients with greater exercise exposure (global longitudinal strain worsening, 0.09% [IQR, 0.01%–0.17%] per 5 MET-hours/week, \(P = 0.02\)). LV function by global longitudinal strain worsened, with 0.08% [IQR, 0.05%–0.12%] per year; \(P < 0.001\), and progression was most evident in patients with desmoplakin genotype \((P\text{ for interaction} <0.001)\). Deterioration of LV function predicted incident ventricular tachyarrhythmia (aborted cardiac arrest, sustained ventricular tachycardia, or implantable cardioverter defibrillator shock) (adjusted odds ratio, 1.1 [IQR, 1.0–1.3] per 1% worsening by global longitudinal strain; \(P = 0.02\), adjusted for time and previous arrhythmic events).

CONCLUSIONS: Greater exercise exposure was associated with worse LV function at first visit of patients with AC but did not significantly affect the rate of LV progression during follow-up. Progression of LV dysfunction was most pronounced in patients with desmoplakin genotypes. Deterioration of LV function during follow-up predicted subsequent ventricular tachyarrhythmia and should be considered in risk stratification.

Key Words: arrhythmogenic cardiomyopathy ■ arrhythmogenic right ventricular cardiomyopathy ■ left ventricular dysfunction ■ ventricular arrhythmia

Arrhythmogenic cardiomyopathy (AC) is an inheritable heart disease characterized by high risk of ventricular tachyarrhythmias (VTAs) and sudden cardiac death. The disease is primarily acquired by autosomal dominant inheritance of dysfunctional genes encoding cardiac desmosomal proteins, and it exhibits variable penetrance and expressivity. AC has long been referred to as arrhythmogenic right ventricular cardiomyopathy because of the high prevalence of right ventricular (RV) disease...
manifestation, but left ventricular (LV) disease manifesta-
tion is increasingly recognized and has been re-
ported to defer worse clinical prognosis.2,3 Exercise exposure increases disease penetrance and risk of VTA,4–6 and exercise restriction is recommended to all patients with ac-

What Are the Clinical Implications?
- Exercise moderation at the time of diagnosis may not resolve LV dysfunction but may halt the disease progression and should be re-

Nonstandard Abbreviations and Acronyms

AC arrhythmogenic cardiomyopathy
GLS global longitudinal strain
VTA ventricular tachyarrhythmia

CLINICAL PERSPECTIVE

What Is New?
- Greater exercise exposure is associated with left ventricular (LV) dysfunction and is common in patients with arrhythmogenic cardiomyopathy.
- Patients with arrhythmogenic cardiomyopathy with desmoplakin mutations have the most pronounced deterioration of LV function during follow-up.
- Deterioration of LV function during follow-up can predict subsequent ventricular tachyarrhythmias.

METHODS

The data that support the findings of this study are available from the corresponding author upon reason-
able request. Consecutive patients with AC diagnosed at the Unit for Genetic Cardiac Diseases, Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, were included in a longitudinal cohort study. Newly diagnosed patients and further repeated measures were included in the analysis that comple-
mented a previously published database of 598 assesse-
ments in 144 patients.10 The first diagnosed patient in a family was defined as the proband, and all probands fulfilled definite diagnosis according to the Task Force Criterias of 2010.11 Consenting probands were tested for genetic variants known to be associated with AC, and family members of mutation-positive probands under-

Cardiac Imaging

Echocardiography is the preferred cardiac imaging modality during follow-up of patients with AC in our clinic. Comprehensive scans were performed at the time of inclusion in all patients and regularly during follow-up at our cardiomyopathy clinic (Vivid 7, E9 or E95, subsequently analyzed offline on EchoPac ver-

This study aimed to assess the association be-
tween recent exercise exposure and LV disease man-
ifestation in patients with AC and to explore whether the disease trajectory is affected by exercise history and different genotypes. We hypothesized that greater exercise exposure would correlate with worse LV function and that progressive LV dysfunction would predict incident VTA.
LV ejection fraction (EF) was measured by the bi-plane Simpson method, and global longitudinal strain (GLS) was assessed by speckle tracking analyses and reported as the average peak negative systolic strain in 16 segments.15–17 LV dysfunction was defined as abnormal EF, <54% for women and 52% for men, according to the chamber quantification recommendations18 or abnormal GLS, worse than −18%, according to the expert consensus document for multimodality imaging in patients with AC.17 Analyses of repeated observations within patients were always performed by a single observer, and all analyses were performed before adjudication of incident VTA.

RV size and function were assessed at baseline by echocardiography in all patients and by cardiac magnetic resonance imaging in a subgroup of patients on clinical indication (1.6-T unit Magnetom Sonata, Vision Plus or Avanto Siemens, Erlangen, Germany) using a phased-array body coil. RV dysfunction was defined in accordance with recommendations as fractional area change ≤40% or tricuspid plane annulus systolic excursion <17 mm from an echocardiographic RV-focused 4-chamber view, or RV EF<40% by cardiac magnetic resonance.11,17 RV dilation was defined as increased proximal RV outflow tract diameter ≥32 mm or increased RV basal diameter >41 mm by echocardiography17 or increased indexed RV end-diastolic volume assessed by cardiac magnetic resonance (>100 mL/m² for women and >110 mL/m² for men).11

Ventricular Tachyarrhythmia
The occurrence of cardiac arrest, documented sustained ventricular tachycardia (>100 beats per minute for >30 seconds19), or appropriate implantable cardioverter defibrillator shock were collectively defined as VTA. These events were adjudicated retrospectively at the time of inclusion and prospectively during follow-up. The time from baseline to first event during follow-up was noted, and the time point of the final echocardiographic assessment before an event was defined as the moment of impending VTA.

In a subsequent analysis, we defined a harder arrhythmic end point “life-threatening VTA” as cardiac arrest, ultra-fast ventricular tachycardia (>250 beats/min), or ventricular fibrillation terminated by an implantable cardioverter defibrillator shock, or hemodynamically unstable ventricular tachycardia occurring during follow-up. These events were timed in the same way as VTA. The harder end point is of great interest in the subgroup of patients who present without arrhythmic events.

Statistical Analysis
Values were reported as mean±SD, number with percentages, median with interquartile range (IQR), or regression coefficients with standard error, as appropriate. Data summary measures were compared using generalized estimating equations to accommodate data dependence by patient relatedness. To account for dependence and different number of observations per individual, the association between exercise exposure and LV function at inclusion and the subsequent impact on LV disease trajectory during follow-up was assessed by linear mixed-model regression with exchangeable covariance structure and patient relatedness and repeated individual observations as 2 levels of random effects. The impact of desmoplakin mutation and exercise exposure on progression of LV disease manifestation were assessed by interaction analysis in linear mixed-model regressions. We performed plots of the fitted mean linear response over time of the patient groups of interest to visualize the trajectories of LV function during follow-up. The impact of LV disease progression on the risk of impending VTA during follow-up was assessed using generalized estimating equations of the repeated LV functional assessments with binomial family, logit link, and independent correlation structure, adjusting for the effect of patient relatedness, elapsed time, and previous ventricular arrhythmia. The outcome analyses were repeated in the subgroup of patients who presented without previous arrhythmic events together with the harder arrhythmic end point “life-threatening VTA,” both adjusted for elapsed time. Two-sided P values <0.05 were considered significant. Statistical analyses were performed using Stata SE 16.0 (StataCorp LLC, College Station, TX).

RESULTS
We included 168 patients (50% probands, 45% women, 40±16 years old, 91 different families) with >1 complete echocardiography exam, in total 715 echocardiographic exams, 4.1±1.7 exams per patient, and with median follow-up 7.6 (IQR, 5.4–10.9) years. The median time between each exam was 1.6 (IQR, 1.1–2.9) years. The shortest interval was 2 months, and the longest was 17.3 years. Complete exercise data were available in 146 (87%) patients. Median exercise dose at inclusion was 14.5 (IQR, 12–40) MET-hours/week. Twenty-five different pathogenic mutations were found in 55 different families (Table S1). Pathogenic mutations in the plakophilin-2 gene were found in 112 (67%) patients, and 20 (12%) patients had pathogenic mutations in non-plakophilin-2 genes (10 desmoglein 2, 9 desmoplakin, and 1 cadherin-2 gene). Among the 84 probands, 34 (38%) had plakophilin-2 mutations, 5 (6%) had desmoglein-2 mutations, and 8 (10%) had desmoplakin mutations, and 1 had cadherin-2 mutation. Thirty-six (46%) probands with definite AC did not have documented
pathogenic variants (22 with negative Sanger sequencing, 12 with negative high-throughput screening, and 2 who did not consent to genetic testing).

**LV Dysfunction**

LV dysfunction was evident in 62 (37%) patients at first assessment. Patients presenting with LV dysfunction had greater exercise exposure than those presenting without LV dysfunction [36 [IQR, 12–50] MET-hours/week versus 14 [IQR, 12–24] MET-hours/week; \(P=0.02\); Table 1], and LV dysfunction was more prevalent at presentation in male patients than in female patients (60 [57%] versus 16 [26%]; \(P=0.003\); Table 1). RV dysfunction and RV dilation were more prevalent in patients with LV dysfunction than in those without (Table 1). Probands had worse LV function than mutation-positive family members at first assessment (EF, 55±9 versus 59±4; \(P<0.001\); and GLS, −17.8±3.7 versus −20.1±2.3; \(P<0.001\)). Among patients with plakophilin-2 mutations (n=112), LV dysfunction was evident in 39 (35%), and those with LV dysfunction had greater exercise exposure (25 [IQR, 12–56] MET-hours/week versus 12 [IQR, 10–18] MET-hours/week; \(P=0.02\)). LV dysfunction was evident in 56% (5/9) of patients with desmoplakin

### Table 1. Baseline Characteristics of 168 Patients With Arrhythmogenic Cardiomyopathy Without and With Left Ventricular Dysfunction at Presentation

|                      | All n=168 | No LV Dysfunction n=106 | LV Dysfunction n=62 | \(P\) Value |
|----------------------|-----------|-------------------------|---------------------|-------------|
| **Age, y**           | 40±16     | 40±16                   | 41±16               | 0.87        |
| **BSA, m²**          | 1.9 (1.8–2.1) | 1.9 (1.8–2.1)       | 2.0 (1.9–2.2)       | 0.09        |
| **Definite diagnosis by TFC, n (%)** | 98 (68) | 55 (52) | 43 (69) | <0.001 |
| **Female sex, n (%)** | 76 (45) | 60 (57) | 16 (26) | 0.003 |
| **Exercise dose, MET-h/wk, n=146** | 15 (12–40) | 14 (12–25) | 36 (12–51) | 0.02 |
| **AA medication, n (%)** | 23 (14) | 7 (7) | 16 (27) | <0.001 |
| **Amiodarone, n (%)** | 6 (4) | 2 (2) | 4 (7) | 0.27 |
| **Flecainide, n (%)** | 5 (3) | 0 (0) | 5 (8) | 0.002 |
| **Sotalol, n (%)** | 12 (7) | 5 (6) | 7 (12) | 0.12 |
| **Beta blocker, n (%)** | 50 (31) | 30 (29) | 20 (34) | 0.32 |
| **Mutation, n (%)** | 132 (79) | 85 (80) | 47 (76) | 0.51 |
| **Caderhin-2, n (%)** | 1 (0) | 1 (1) | 0 (--) | -- |
| **Desmoglein-2, n (%)** | 10 (6) | 7 (7) | 3 (5) | 0.69 |
| **Desmoplakin, n (%)** | 9 (5) | 4 (4) | 5 (8) | 0.20 |
| **Plakophilin-2, n (%)** | 112 (67) | 73 (69) | 39 (63) | 0.46 |
| **Probands, n (%)** | 84 (50) | 43 (41) | 41 (66) | <0.001 |
| **VTA, n (%)** | 58 (35) | 30 (28) | 28 (45) | 0.01 |
| **Syncope, n (%)** | 66 (40) | 36 (34) | 30 (49) | 0.01 |
| **Cardiac imaging** | | | | |
| **LV EF, %** | 57±7 | 59±4 | 52±9 | n.a |
| **LV GLS, %** | −19.0±3.3 | −20.6±2.0 | −16.3±3.1 | n.a |
| **RV FAC, %** | 39±10 | 42±9 | 35±10 | <0.001 |
| **TAPSE, mm** | 20±5 | 21±5 | 18±6 | <0.001 |
| **RV EF, %** | 47±11 | 49±11 | 42±11 | 0.003 |
| **RV dysfunction, n (%)** | 94 (56) | 53 (50) | 41 (66) | 0.03 |
| **RVOT, mm** | 36±8 | 34±7 | 38±9 | 0.006 |
| **RVD, mm** | 42±8 | 40±7 | 45±9 | <0.001 |
| **RV EDVI, mL/m** | 107±36 | 103±39 | 114±29 | 0.13 |
| **RV dilation, n (%)** | 116 (69) | 68 (64) | 48 (77) | 0.008 |

Values are mean±standard deviation, median (interquartile range), or frequency (percentages) compared by generalized estimating equations accounting for dependence by relatedness of patients.

Abbreviations: AA indicates antiarrhythmic; BSA, body surface area; EF, ejection fraction; FAC, fractional area change; GLS, global longitudinal strain; LV, left ventricle; MET-h/wk, metabolic equivalents task × hours per week; RV, right ventricular; RVD, right ventricular diameter; RVOT, right ventricular outflow tract; TAPSE, tricuspid annular plane systolic excursion; TFC, task force criteria; and VTA, ventricular tachyarrhythmia.

*Assessed by echocardiography in all patients.

1Assessed by cardiac magnetic resonance imaging in a subgroup of 75 patients.
mutations at first assessment, versus 43% (48/119) of patients without desmoplakin mutations (P=0.27).

**Deterioration of LV Function**

GLS was assessed in 648 (91%) exams and demonstrated a subtle but clear decline of LV function (−18.5 [IQR, −19.2 to −18.3]% at presentation, with 0.08% [IQR, 0.05%–0.12%] worsening per year; P<0.001). EF was assessed in 699 (98%) echocardiographic exams. We observed no general decline in EF during follow-up (57.1 [IQR, 56.0–58.1] at presentation with 0.0% [IQR, −0.1% to 0.1%] worsening per year; P=0.56). There was no difference in the trajectory of LV function between probands and family members (P for interaction 0.85 and 0.83 for deterioration of EF and GLS, respectively).

A total of 628 echocardiographic assessments were analyzed in the 146 patients with complete exercise data. Greater exercise exposure correlated with worse EF and GLS at first echocardiography, but previous exercise habits did not affect the deterioration of LV function during follow-up, neither by GLS nor by EF (Table 2, Figure 1).

Patients with mutations in the desmoplakin gene had worse progression of LV function during 39 follow-up echocardiographic exams than patients without desmoplakin mutations (EF, −0.82% [IQR, −1.31% to −0.33%] per year versus 0.05% [−0.04% to 0.14%] per year; P=0.001; and less clear by GLS+0.18% [IQR, −0.01% to 0.38%] per year versus +0.08% [IQR, 0.04%–0.11%] per year; P=0.06; Figure 2). The impact of desmoplakin gene mutations was also independent of exercise exposure, suggesting that EF declined 0.8% more per year in patients with desmoplakin mutations than in other patients independently of exercise exposure (adjusted beta for interaction −0.8 [IQR, −1.3 to −0.3] per year; P=0.003; Table S2).

Patients with LV dysfunction at first examination did not have more pronounced progression of LV dysfunction during follow-up than patients presenting with normal LV function. In fact, the analyses demonstrated an opposite trend, with steeper worsening of both EF and GLS in patients presenting with normal LV function (EF, 0.29% [IQR, 0.10%–0.47%] worse per year; P=0.003; and GLS, 0.22% [0.15%–0.30%] worse per year; P<0.001; Figure S1). The progression of LV dysfunction was not affected by the presence of RV dysfunction or RV dilation at baseline (Figure S1).

### LV Dysfunction and Prediction of VTAs

VTA occurred in 77 patients, of whom 58 (35% of all patients) had experienced events at or before baseline. Nineteen patients had their first VTA, and 35 (60%) had subsequent incident VTA during follow-up (in total 54 patients with events after median 1.3 years [IQR, 0.4–3.5]). Odds of impending VTA increased by 14% for every 1% absolute deterioration of GLS during follow-up, adjusted for elapsed time and history of previous VTA (adjusted odds ratio [OR] 1.1 [IQR, 1.0–1.3]; P=0.02; Figure 3). Importantly, this was also evident in the subgroup of patients presenting without previous arrhythmia (n=110; 444 echocardiographic exams), with 35% increased odds of impending VTA for every 1% worsening in GLS (adjusted OR, 1.4 [IQR, 1.2–1.6]; P<0.001, adjusted for time; Figure 3). The effect was less clear for deterioration in EF in the total population (adjusted OR, 1.2 [IQR, 0.9–1.4]; P=0.23, by 5% reduction in EF, adjusted for time and history of previous VTA), but in the subgroup of patients presenting without arrhythmia, 50% increased odds was observed for every 5% fall in EF during follow-up (adjusted OR, 1.5 [IQR, 1.1–2.2]; P=0.02, adjusted for time). These observations were independent of the underlying pathogenic mutation (Table S3).

Thirteen patients without previous events had life-threatening VTA during follow-up. No patients died suddenly during follow-up. One had resuscitated cardiac arrest. Five had ultra-fast ventricular tachycardia or ventricular fibrillation that was terminated by an implantable cardioverter defibrillator shock. Seven had hemodynamically unstable ventricular tachycardia. The odds of impending life-threatening VTA increased by 25% by every 1% worsening in EF during follow-up (adjusted OR, 1.3 [IQR, 1.1–1.5]; P=0.006, adjusted for time) and by 50% by every 5% fall in EF during follow-up (adjusted OR, 1.5 [IQR, 1.1–2.1]; P=0.02, adjusted for time).

### Table 2. Relationship Between Exercise Exposure and Left Ventricular Function During Long-Term Follow-Up With 628 Echocardiographic Exams in 146 Patients With Arrhythmogenic Cardiomyopathy and Known Exercise Habits at Presentation

| Variable                                | Beta  | 95% CI       | P Value |
|-----------------------------------------|-------|--------------|---------|
| GLS (constant), n=584 (93%)             | −19.4 | −19.9 to −18.6 | 0.008   |
| Time, y                                 | 0.07  | 0.02 to 0.12  | 0.008   |
| Exercise dose (5 MET-h/wk)              | 0.09  | 0.01 to 0.17  | 0.02    |
| Interaction: Time×Exercise dose         | 0.002 | −0.003 to 0.008 | 0.44   |
| EF (constant), n=616 (98%)              | 58    | 57 to 59     | <0.05   |
| Time, y                                 | 0.02  | −0.10 to 0.14 | 0.72    |
| Exercise dose (5 MET-h/wk)              | −0.18 | −0.36 to −0.003 | <0.05  |
| Interaction: Time×Exercise dose         | 0.004 | −0.010 to 0.018 | 0.57   |

Values are regression coefficients with 95% CIs. P values by linear mixed-model regression with exchangeable covariance structure and random effects by families and individuals.

Abbreviations: EF indicates ejection fraction; GLS, global longitudinal strain; and MET-h/wk, metabolic equivalents of task×hours per week.
DISCUSSION

This study showed LV dysfunction at the time of presentation in more than one-third of patients with AC. Greater exercise exposure was associated with LV dysfunction at first visit, highlighting the deleterious effects of exercise on biventricular function in AC. However, we found no effect of previous exercise exposure on the progression of LV dysfunction after established AC diagnosis, indicating no accelerated LV disease progression by previous exercise. LV disease progression was most pronounced in desmoplakin genotype-positive patients, supporting previous reports of LV vulnerability in this genotype. Deterioration of LV function during follow-up predicted incident VTA.

Exercise Exposure

Greater exercise exposure was associated with worse LV function at presentation but did not affect the rate of LV deterioration during follow-up. Interestingly, previous exercise exposure did not seem to accelerate LV disease after exercise was restricted at the time of diagnosis. On the other hand, we found no improvement or normalization of LV function after exercise restriction, suggesting an irreversible exercise-induced dysfunction.

It is well established that exercise exposure is associated with disease severity in patients with AC, but previous reports have been single-observation studies focusing on RV disease manifestation. This study highlights for the first time the association between exercise exposure and LV dysfunction. It is believed that RV disease in exercise-exposed patients with AC is caused by the mechanical stress imposed on the RV wall by increased loading conditions during exercise. Stretching forces in the context of dysfunctional desmosomes disrupt the cellular signaling and intercellular adhesions, triggering arrhythmias and fibrofatty replacement. While the RV is famously vulnerable to these mechanisms, the LV is also exposed to increased loading conditions during exercise, and
therefore exercise-induced LV alterations must be expected in AC.

Adaptive LV remodeling is frequently encountered in athletes. We do not believe that the differences in LV function at baseline were attributable to physiological exercise adaptations. LV function did not recover in our patients, suggesting irreversible and maladaptive mechanisms in patients with AC, with the result of LV dysfunction probably induced by higher exercise doses.

We demonstrated LV disease progression by repeated assessment of GLS, while EF measurements were relatively stable. GLS provides a more sensitive and accurate estimation of LV function than EF, and our findings support the use of GLS as the primary index of LV function in patients with AC.

**Deterioration of LV Function**

Previous studies have reported higher prevalence of reduced EF (<55%) in patients with AC with desmoplakin genotypes than in other genotypes. Our study supports this observation and additionally demonstrates a more pronounced progression of LV dysfunction in patients with desmoplakin mutations. However, and importantly, we observed deterioration of LV function also in patients without desmoplakin highlighting a genotype-independent biventricular disease.

Our arbitrary definition of LV dysfunction may be subject to debate. Global longitudinal strain is reported to be superior to EF when assessing LV function in several scenarios, but it is not globally implemented in clinical practice. Therefore, we have used a combined definition that may be unusual but aims to detect also early LV dysfunction. Patients with LV dysfunction at the time of diagnosis did progress more rapidly during follow-up than those presenting with normal LV function. In contrast, we observed a trend toward more pronounced LV progression in patients with normal LV function at first assessment. This observation may have several explanations. First, present data suggested that cessation of high-intensity exercise may halt progression of LV disease. Second, there may be a component of regression to the sample mean. Most importantly, our data demonstrate that absence of LV dysfunction at first presentation does not exclude subsequent deterioration of LV function.

Presence of RV disease manifestation at the time of diagnosis did not predict LV disease progression. This interesting observation suggests that RV and LV disease manifestation may exist somewhat independent
of each other and underscores the importance of careful LV assessment in patients with AC.

**Risk of VTA**

The odds of impending VTA increased when LV function deteriorated during follow-up, independently of genotype. The association between LV dysfunction and adverse outcome is both intuitive and previously described, but this is the first report showing the chronological sequence of LV disease progression leading up to an arrhythmic event. The value of recognizing LV dysfunction was particularly convincing in the subgroup of patients presenting without previous VTA, in whom worsening of both EF and GLS predicted events. Life-threatening VTA occurred during follow-up in only 13 patients without previous arrhythmic events. However, this underpowered analysis suggested that deterioration of LV function may also be valuable in predicting harder arrhythmic endpoints. This must be assessed in future studies, but emerging LV dysfunction should raise awareness for primary preventive implantable cardioverter defibrillator evaluation.

**LIMITATIONS**

This was a single-center longitudinal study with uncertain external validity. The observational data do not allow for causal inference. The main limitation is the single-time-point ascertainment of exercise habits, and the retrospective assessment of exercise exposure is subject to recall bias and possibly reporting bias. All patients were recommended to abstain from high-intensity exercise based on the best knowledge at the time, but we do not have data on adherence to exercise restriction recommendations. Future studies should assess exercise exposure as a time-varying covariate during follow-up to fully elucidate this interaction. Fulfillment of Task Force Criteria introduced in 2010 was assessed retrospectively in individuals presenting earlier. Our center does not routinely obtain endomyocardial biopsy material from patients with AC, and therefore we cannot firmly exclude differential diagnoses in the mutation-negative probands. The number of patients with non-plakophilin-2 mutations was low and was only partially compensated for by the repeated assessments. The pronounced LV functional deterioration in patients with desmoplakin mutations should therefore be interpreted with care.
The main arrhythmic outcome was relatively weak, including hemodynamically stable ventricular tachycardia, and hard arrhythmic outcome analysis was underpowered.

CONCLUSIONS
LV dysfunction was detected in one-third of patients with AC at presentation and was associated with greater exercise exposure. LV function deteriorated during follow-up and was most pronounced in the desmoplakin genotype positive. LV deterioration was independent of previous exercise exposure, indicating no accelerated effect by greater previous exercise exposure. Exercise cessation did not seem to resolve LV dysfunction but may halt the progression. Deterioration of LV function during follow-up predicted impending VTAs and should be considered in risk assessments of patients with AC.

ARTICLE INFORMATION
Received September 22, 2020; accepted February 23, 2021.

Affiliations
From the Department of Cardiology, Oslo University Hospital, Rikshospitalet, Norway (Ø.H.L., M.C., C.R., M.R., E.L., J.O.B., V.A., K.H.H.); Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Norway (O.H.L., M.C., C.R., K.H.H.); and Unit for Cardiac and Cardiovascular Genetics, Oslo University Hospital, Norway (M.P.B.).

Acknowledgments
The authors are grateful to all the patients who consented to be included in the present study, and to the staff at the Unit for Genetic Cardiac Disorders and Section of Echocardiography at the Department of Cardiology, Oslo University Hospital, Rikshospitalet.

Sources of Funding
This work was supported by the South-Eastern Norway Regional Health Authority (grant #201094), the Center for Cardiological Innovation supported by the Research Council of Norway (grant #203489) and Precision Health Center for optimized cardiac care (ProCardio) : #309762.

Disclosures
None.

Supplementary Material
Tables S1–S3
Figure S1

REFERENCES
1. Corrado D, Basso C, Judge DP. Arrhythmogenic cardiomyopathy. Circ Res. 2017;121:784–802. DOI: 10.1161/CIRCRESAHA.117.309345.
2. Lie OH, Rootewit-Norberg C, DeGaard LA, Leren IS, Stokke MK, Edvardsen T, Haugaa KH. Prediction of life-threatening ventricular arrhythmia in patients with arrhythmogenic cardiomyopathy: a primary prevention cohort study. J Am Coll Cardiol Img. 2018;11:1377–1386. DOI: 10.1016/j.jcmg.2018.05.017.
3. Mast TP, Teske AJ, vd Heijden JF, Groeneweg JA, Te Riele ASJM, Velthuis BK, Hauer RNW, Doevendans PA, Cramer MJ. Left ventricular involvement in arrhythmogenic right ventricular dysplasia/cardiomyopathy assessed by echocardiography predicts adverse clinical outcome. J Am Soc Echocardiogr. 2015;28:1103–1113. DOI: 10.1016/j.echo.2015.04.015.
4. Lie OH, DeGaard LA, Saberniak J, Rootewit-Norberg C, Stokke MK, Edvardsen T, Haugaa KH. Harmful effects of exercise intensity and exercise duration in patients with arrhythmogenic cardiomyopathy. JACC Clin Electrophysiol. 2018;4:744–753. DOI: 10.1016/j.jacep.2018.01.010.
5. Ruwald AC, Marcus F, Estes NA 3rd, Link M, McNitt S, Polonsky B, Calkins H, Trowin JA, Moss AJ, Zareba W. Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2015;36:1735–1743. DOI: 10.1093/eurheartj/ehv110.
6. James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, Tedford RJ, Judge DP, Calkins H. Exercise increases age-related permeance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2015;62:1290–1297. DOI: 10.1016/j.jacc.2013.06.033.
7. Trowin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, Daubert JP, de Chilou C, DePascalae EC, Desai MY, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019;16:e301–e372. DOI: 10.1016/j.hrthm.2019.05.007.
8. Hoornije ET, Te RijtJP, James CA, Pilchou K, Basso C, Judge DP, Bezzina GR, van Tintelen JP. Arrhythmogenic cardiomyopathy: pathology, genetics, and concepts in pathogenesis. Cardiovasc Res. 2017;113:1521–1531. DOI: 10.1093/cvr/cvx150.
9. Akdis D, Saguner AM, Burri H, Medeiros-Domingo A, Matter CM, Ruschitzka F, Tanner FC, Brunkhorst C, Duru F. Clinical predictors of left ventricular involvement in arrhythmogenic right ventricular cardiomyopathy. Am Heart J. 2020;223:34–43. DOI: 10.1016/j.ahj.2020.01.019.
10. Chiuvelescu M, Lie OH, Popescu BA, Skulstad H, Edvardsen T, Jurcut RO, Haugaa KH. High penetrance and similar disease progression in probands and in family members with arrhythmogenic cardiomyopathy. Eur Heart J. 2019;41:1401–1410. DOI: 10.1093/eurheartj/ehz570.
11. Marcus FI, McKenna WJ, Niebauer J, Pessier D, Basso C, Bueck MD, Calkins H, Corrado D, Cox M, Cowpe JT, Daubert JP, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121:1533–1541. DOI: 10.1161/CIRCULATIONAHA.108.840827.
12. Richards S, Aziz N, Bale S, Bick D, Das S, Gastner-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:403–424. DOI: 10.1038/gim.2015.30.
13. Pelliccia A, Solberg EE, Papadakis M, Adamri PE, Bifti A, Caselli S, La Gerche A, Niebauer J, Pessier D, Schmied CM, et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2019;40:19–33. DOI: 10.1093/eurheartj/ehy370.
14. Pelliccia A, Zipes DP, Maron BJ. Bethesda Conference #36 and the European Society of Cardiology consensus recommendations revisited a comparison of U.S. and European criteria for eligibility and disqualification of competitive athletes with cardiovascular abnormalities. J Am Coll Cardiol. 2008;52:1990–1996. DOI: 10.1016/j.jacc.2008.08.055.
15. Voigt J-U, Pedrizetti G, Lysansky P, Marwick TH, Houle B, Baumann R, Pedri S, Ito Y, Abe Y, Metz S, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 2015;16:11–11. DOI: 10.1093/ehjci/jeu184.
16. Corrado D, van Tintelen PJ, McKenna WJ, Hauer RNW, Anastastakis A, Aismaki A, Basso C, Bueck MD, Brunkhorst C, Bucciarelli-Ducci C, et al. Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. Eur Heart J. 2020;41:1414–1429. DOI: 10.1093/eurheartj/ehz669.
17. Haugaa KH, Basso C, Badano LP, Bucciarelli-Ducci C, Cardim N, Gaemperli O, Gallenier M, Habib G, Knaut J, Lancellotti P, et al. Comprehensive multi-modality imaging approach in arrhythmogenic cardiomyopathy an expert consensus document of the European Association of Cardiovascular Imaging. Eur J Heart Cardiovasc Imaging. 2017;18:237–253. DOI: 10.1093/ehjci/jew229.
18. Lang RM, Badano LP, Mor-Avi V, Alfaiad J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography
and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2015;16:233–270. DOI: 10.1093/ehjci/jev014.
19. Pedersen CT, Kay GN, Kalman J, Borggreve M, Della-Bella P, Dickfeld T, Dorian P, Huijbers H, Kim Y-H, Knight B, et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. *European*. 2014;16:1257–1283. DOI: 10.1093/europace/euv194.
20. Galderisi M, Cardim N, D'Andrea A, Bruder O, Cosyns B, Davin L, Donal E, Edvardsen T, Freitas A, Habib G, et al. The multi-modality cardiac imaging approach to the athlete's heart: an expert consensus of the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2015;16:353. DOI: 10.1093/ehjci/jeu323.
21. Haugaa KH, Edvardsen T. Global longitudinal strain: the best biomarker for predicting prognosis in heart failure? *Eur J Heart Fail*. 2016;18:1340–1341. DOI: 10.1002/ejhf.632.
22. Stokke TM, Hasselberg NE, Smedsrud MK, Sarvari SI, Haugaa KH, Smiseth OA, Edvardsen T, Remme EW. Geometry as a confounder when assessing ventricular systolic function: comparison between ejection fraction and strain. *J Am Coll Cardiol*. 2017;70:942–954. DOI: 10.1016/j.jacc.2017.06.046.
23. Bhonsale A, Groeneweg JA, James CA, Dooljes D, Tichnell C, Jongbloed JDH, Murray B, te Riele ASJM, van den Berg MP, Bikker H, et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. *Eur Heart J*. 2015;36:847–855. DOI: 10.1093/eurheartj/ehu509.
Supplemental Material
Table S1. Results of genetic testing in 168 patients with arrhythmogenic cardiomyopathy.

| Mutation                                                                 | Individuals, n (%) | Families, n (%) |
|--------------------------------------------------------------------------|--------------------|----------------|
| **No identified mutation**                                               | 36 (21.4)          | 36 (39.6)      |
| c.2145+2T>A (seq: NM_004572.3) intron 10 in PKP2                        | 55 (32.7)          | 18 (19.8)      |
| c.2197C>G, c.2198_2202delACACC (seq: NM_004572.3) exon 11 in PKP2       | 29 (17.3)          | 8 (8.8)        |
| Deletion of Promoter, exon 1 and exon 2 in PKP2                         | 15 (8.9)           | 2 (2.2)        |
| c.1952_1955dupGAAG (seq: NM_004572.3) exon 9 in PKP2                    | 4 (2.4)            | 4 (4.4)        |
| c.3059_3062delAGAG (seq: NM_001943.3) exon 15 in DSG2                   | 4 (2.4)            | 3 (3.3)        |
| R46Q (c.137G>A, seq: NM_001943.3) exon 3 in DSG2                       | 4 (2.4)            | 1 (1.1)        |
| c.2300-1G>A (seq: NM_004572.3) intron 11 in PKP2                       | 2 (1.2)            | 1 (1.1)        |
| R425X (c.1273C>T, seq: NM_004415.2) exon 11 in DSP                      | 2 (1.2)            | 1 (1.1)        |
| c.198delG (seq: NM_004572.3) exon 1 in PKP2                             | 1 (0.6)            | 1 (1.1)        |
| A2294G (c.6881C>G, seq: NM_004415.2) exon 24 in DSP                    | 1 (0.6)            | 1 (1.1)        |
| c.223+2T>C (seq: NM_004572.3) intron 1 in PKP2                         | 1 (0.6)            | 1 (1.1)        |
| c.1597dup (seq: NM_004572.3) exon 7 in PKP2                             | 1 (0.6)            | 1 (1.1)        |
| c.2463_2464insAC (seq: NM_004415.2) exon 18 in DSP                      | 1 (0.6)            | 1 (1.1)        |
| c.2489+1G>A (seq: NM_004572.3) intron 12 in PKP2                       | 1 (0.6)            | 1 (1.1)        |
| c.3203_3204delAG (seq: NM_004415.2) exon 23 of DSP                     | 1 (0.6)            | 1 (1.1)        |
| c.5764delA (seq: NM_004415.2) exon 24 in DSP                           | 1 (0.6)            | 1 (1.1)        |
| c.6310delA (seq: NM_004415.2) exon 24 in DSP                           | 1 (0.6)            | 1 (1.1)        |
| D407N (c.1219G>A, seq: NM_001792) exon 9 in CDH2                      | 1 (0.6)            | 1 (1.1)        |
| G48D (c.143G>A, seq: NM_004572.3) exon 1 in PKP2                       | 1 (0.6)            | 1 (1.1)        |
| E1345A (c.4034A>C, seq: NM_004415.2) exon 23 in DSP                    | 1 (0.6)            | 1 (1.1)        |
| GS09E (c.1526G>A, seq: NM_004415.2) exon 12 in DSP                     | 1 (0.6)            | 1 (1.1)        |
| c.148_151delACAG (seq: NM_004572.3) exon 1 in PKP2                     | 1 (0.6)            | 1 (1.1)        |
| S140F (c.419C>T, seq: NM_004572.3) exon 3 in PKP2                      | 1 (0.6)            | 1 (1.1)        |
| T335A (c.1003A>G, seq: NM_001943.3) exon 8 in DSG2                     | 1 (0.6)            | 1 (1.1)        |
| V392I (c.1174G>A, seq: NM_001943.3) exon 9 in DSG2                     | 1 (0.6)            | 1 (1.1)        |

CDH2 = Cadherin 2-gene, DSG2 = Desmoglein 2-gene, DSP = Desmoplakin-gene, PKP2 = Plakophillin 2-gene.
Table S2. Relationship between exercise exposure, pathogenic mutations in desmoplakin gene and left ventricular function during long-term follow-up with 628 echocardiographic exams in 146 patients with arrhythmogenic cardiomyopathy and known exercise habits at presentation

|                          | Beta   | 95% CI      | p     |
|--------------------------|--------|-------------|-------|
| **GLS** (constant), n=584 (93%) | -19.3  | -20.0 to -18.6 |       |
| Time (years)             | 0.06   | 0.01 to 0.11 | 0.03  |
| Exercise dose (5 METhrs/week) | 0.09   | 0.01 to 0.17 | 0.02  |
| Interaction: Time*Exercise dose | 0.003 | -0.003 to 0.008 | 0.33  |
| DSP mutation             | 0.11   | -2.03 to 2.25 | 0.92  |
| Interaction: Time*DSP mutation | 0.22   | 0.02 to 0.42 | 0.03  |
| **EF** (constant), n=616 (98%) | 58     | 56 to 60    |       |
| Time (years)             | 0.06   | -0.07 to 0.18 | 0.37  |
| Exercise dose (5 METhrs/week) | -0.19 | -0.37 to -0.01 | 0.04  |
| Interaction: Time*Exercise dose | 0.002 | -0.012 to 0.016 | 0.76  |
| DSP mutation             | -1.4   | -6.3 to 3.6  | 0.58  |
| Interaction: Time*DSP mutation | -0.8  | -1.3 to -0.3 | 0.004 |

Values are regression coefficients with 95% confidence intervals. P-values by linear mixed model regression with exchangeable covariance structure and random effects by families and individuals. CI = confidence interval, DSP = desmoplakin, EF = ejection fraction, GLS = global longitudinal strain, METhrs/week = metabolic equivalents of task multiplied by hours per week.
Table S3. Prediction of impending ventricular tachyarrhythmia in 168 patients (total population) and 102 patients without previous events (primary prevention), adjusted for genetic basis of disease.

|                                | Odds ratio | 95% CI     | p     |
|--------------------------------|------------|------------|-------|
| **Total population - EF (n=699/168)** |            |            |       |
| Time (1 year)                  | 1.06       | 1.00 to 1.13 | 0.06  |
| Previous event                | 6.50       | 2.84 to 14.86 | <0.001|
| EF (-5%)                       | 1.13       | 0.91 to 1.41 | 0.27  |
| PKP2 mutation                  | 1.02       | 0.39 to 2.66 | 0.96  |
| DSG2 mutation                  | 0.28       | 0.04 to 2.02 | 0.21  |
| DSP mutation                   | 0.68       | 0.14 to 2.93 | 0.64  |
| CDH2 mutation                  | -          | -           | -     |
| **Total population - GLS (n=648/166)** |            |            |       |
| Time (1 year)                  | 1.06       | 0.99 to 1.13 | 0.08  |
| Previous event                | 5.84       | 2.42 to 14.10 | <0.001|
| GLS (1%)                       | 1.13       | 1.00 to 1.27 | 0.04  |
| PKP2 mutation                  | 1.10       | 0.40 to 3.03 | 0.85  |
| DSG2 mutation                  | 0.22       | 0.03 to 1.85 | 0.17  |
| DSP mutation                   | 0.94       | 0.20 to 4.31 | 0.94  |
| CDH2 mutation                  | -          | -           | -     |
| **Primary prevention - EF (n=418/102)** |            |            |       |
| Time (1 year)                  | 1.14       | 1.04 to 1.24 | 0.003 |
| EF (-5%)                       | 1.52       | 1.04 to 2.22 | 0.03  |
| PKP2 mutation                  | 0.44       | 0.12 to 1.68 | 0.23  |
| Mutation          | Odds Ratio | 95% CI         | p-value |
|-------------------|------------|----------------|---------|
| DSG2 mutation     | -          | -              | -       |
| DSP mutation      | -          | -              | -       |
| CDH2 mutation     | -          | -              | -       |

**Primary prevention - GLS**

(n=402/101)

| Time (1 year)    | 1.14       | 1.05 to 1.25  | 0.003   |
| GLS (1%)         | 1.38       | 1.17 to 1.64  | <0.001  |
| PKP2 mutation    | 0.38       | 0.10 to 1.43  | 0.15    |
| DSG2 mutation    | -          | -              | -       |
| DSP mutation     | -          | -              | -       |
| CDH2 mutation    | -          | -              | -       |

Values are odds ratios with 95% confidence intervals, calculated by multivariable generalized estimating equations with binomial family, logit link and independent covariance structure, adjusted for patient relatedness. DSP and DSG mutations were omitted from analyses in the primary prevention subgroups due to lack of events in these patients. CI = confidence interval, CDH2 = Cadherin 2, DSG2 = desmoglein 2, DSP = desmoplakin, EF = ejection fraction, GLS = global longitudinal strain, PKP2 = plakophilin 2.
Figure S1. Left ventricular functional deterioration during follow-up of 168 patients with arrhythmogenic cardiomyopathy with and without functional or structural abnormalities at presentation.

Slopes are fitted mean linear response with 95% confidence intervals for patients with and without LV dysfunction (upper panel), RV dysfunction (mid panel) and RV dilation (lower panel) at presentation. P-values for progression and interaction by linear mixed model regression with random effects for families and individuals and exchangeable covariance structure. EF = ejection fraction, GLS = global longitudinal strain, LV = left ventricle, RV = right ventricle.